ArriVent BioPharma, Inc. Common Stock - Asset Resilience Ratio
ArriVent BioPharma, Inc. Common Stock (AVBP) has an Asset Resilience Ratio of 75.66% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ArriVent BioPharma, Inc. Common Stock (AVBP) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how ArriVent BioPharma, Inc. Common Stock's Asset Resilience Ratio has changed over time. See AVBP net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down ArriVent BioPharma, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is ArriVent BioPharma, Inc. Common Stock worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $264.28 Million | 75.66% |
| Total Liquid Assets | $264.28 Million | 75.66% |
Asset Resilience Insights
- Very High Liquidity: ArriVent BioPharma, Inc. Common Stock maintains exceptional liquid asset reserves at 75.66% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ArriVent BioPharma, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare ArriVent BioPharma, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for ArriVent BioPharma, Inc. Common Stock (2023–2025)
The table below shows the annual Asset Resilience Ratio data for ArriVent BioPharma, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 80.22% | $267.28 Million | $333.17 Million | +27.64pp |
| 2024-09-30 | 52.58% | $144.57 Million | $274.94 Million | -- |
| 2023-09-30 | 0.00% | $0.00 | $163.10 Million | -- |
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutati… Read more